Myriad Genetics (MYGN) EBITDA (2016 - 2025)
Historic EBITDA for Myriad Genetics (MYGN) over the last 17 years, with Q3 2025 value amounting to -$23.3 million.
- Myriad Genetics' EBITDA fell 1650.0% to -$23.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$420.5 million, marking a year-over-year decrease of 26312.61%. This contributed to the annual value of -$123.5 million for FY2024, which is 5202.02% up from last year.
- Per Myriad Genetics' latest filing, its EBITDA stood at -$23.3 million for Q3 2025, which was down 1650.0% from -$329.2 million recorded in Q2 2025.
- In the past 5 years, Myriad Genetics' EBITDA ranged from a high of -$17.8 million in Q2 2022 and a low of -$329.2 million during Q2 2025
- Over the past 5 years, Myriad Genetics' median EBITDA value was -$39.0 million (recorded in 2024), while the average stood at -$57.5 million.
- Per our database at Business Quant, Myriad Genetics' EBITDA skyrocketed by 6954.61% in 2021 and then crashed by 80191.78% in 2025.
- Quarter analysis of 5 years shows Myriad Genetics' EBITDA stood at -$43.1 million in 2021, then decreased by 21.11% to -$52.2 million in 2022, then soared by 39.85% to -$31.4 million in 2023, then fell by 24.2% to -$39.0 million in 2024, then skyrocketed by 40.26% to -$23.3 million in 2025.
- Its EBITDA stands at -$23.3 million for Q3 2025, versus -$329.2 million for Q2 2025 and -$29.0 million for Q1 2025.